Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness: the 3T/2R (Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel).

摘要

To the Editor: Large interindividual variability in the response to aspirin and clopidogrel (oral antiplatelet agents [OAA]) is known to exist, and previous studies showed that poor response to OAA is associated with higher risk of ischemic complications after percutaneous coronary intervention (PCI) (1-3). Whether poor responders to OAA display similar inadequate platelet inhibition (PI) also after glycoprotein (GP) Ilb/IIIa inhibitor administration remains undefined.